Methods and compositions for transgene expression
AssigneesUniversity of Iowa Research Foundation, Spirovant Sciences, Inc.
InventorsJohn F. Engelhardt, Ziying Yan, Yinghua Tang, Eric Yuen, Shen Lin
Life of this patent
Estimating the term…
Loading patent…
AssigneesUniversity of Iowa Research Foundation, Spirovant Sciences, Inc.
InventorsJohn F. Engelhardt, Ziying Yan, Yinghua Tang, Eric Yuen, Shen Lin
Estimating the term…
The disclosure provides methods of expressing a transgene in a cell, methods of treating disorders in a subject in need thereof, and pharmaceutical compositions. In particular, the methods involve contacting a cell (e.g., a cell of a subject suffering from a disorder such as cystic fibrosis) with a recombinant adeno-associated virus (rAAV) that includes, in one embodiment, an AV.TL65 capsid protein and a polynucleotide that includes a transgene in combination with an augmenter of AAV transduction, thereby expressing the transgene in the cell. The disclosure also provides pharmaceutical compositions that include an rAAV that includes, in one embodiment, an AV.TL65 capsid protein and a polynucleotide including a transgene in combination with one or more augmenters.
A method of expressing a transgene in a cell, the method comprising contacting the cell with (i) a recombinant adeno-associated virus (rAAV) comprising an AV.TL65 capsid protein, or a variant thereof, and a polynucleotide comprising a transgene;
(canceled)
(canceled)
A method of treating a disorder in a subject in need thereof, the method comprising administering to the subject (i) a recombinant adeno-associated virus (rAAV) comprising an AV.TL65 capsid protein, or a variant thereof, and a polynucleotide comprising a therapeutic transgene;
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising (i) an rAAV comprising an AV.TL65 capsid protein, or a variant thereof, and a polynucleotide comprising a transgene;
26-28. (canceled)
Dependencies are inferred from the claim text.